Trial Profile
Pharmacokinetics of Lanabecestat (LY3314814) in Subjects With Impaired Renal Function
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 06 Jul 2018
Price :
$35
*
At a glance
- Drugs Lanabecestat (Primary) ; Iohexol
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 26 Jun 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 07 Jun 2018 New trial record